nach oben

Erschienen in:

01.01.2016

A perspective on sympathetic renal denervation in chronic congestive heart failure

verfasst von: Raef Madanieh, Mohammed El-Hunjul, Hassan Alkhawam, Constantine E. Kosmas, Abed Madanieh, Timothy J. Vittorio

Erschienen in: Heart Failure Reviews | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Medical therapy has indisputably been the mainstay of management for chronic congestive heart failure. However, a significant percentage of patients continue to experience worsening heart failure (HF) symptoms despite treatment with multiple therapeutic agents. Recently, catheter-based interventional strategies that interrupt the renal sympathetic nervous system have shown promising results in providing better symptom control in patients with HF. In this article, we will review the pathophysiology of HF for better understanding of the interplay between the cardiovascular system and the kidney. Subsequently, we will briefly discuss pivotal renal denervation (RDN) therapy trials in patients with resistant hypertension and then present the available evidence on the role of RDN in HF therapy.

Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN (1984) The neurohumoral axis in congestive heart failure. Ann Intern Med 101(3):370–377PubMedCrossRef

Hasking GJ, Esler MD, Jennings GL, Burton D, Korner P (1986) Norepinephrine spillover to plasma in patients with congestive heart failure: evidence for increased overall and cardiorenal sympathetic nervous activity. Circulation 73(4):615–621PubMedCrossRef

Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, Esler MD (1993) Cardiac sympathetic activity in congestive heart failure: evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 88(1):136–145PubMedCrossRef

Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD (1994) Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 23(3):570–578CrossRef

Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD (2003) Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108(5):560–565PubMedCrossRef

Schwarlz PJ. Billman GE, Stone HL (1984) Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia in dogs with healed myocardial infarction. Circulation 69(4):790–800CrossRef

Meredith IT, Broughton A, Jennings GL, Esler MD (1991) Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 325(9):618–624PubMedCrossRef

Mann DL, Kent RL, Parsons B, Cooper G (1995) Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85(2):790–804CrossRef

Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD (1995) Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26(5):1257–1263PubMedCrossRef

10.

Azevedo ER, Newton GE, Floras JS, Parker JD (2000) Reducing cardiac filling pressure lowers norepinephrine spillover in patients with chronic heart failure. Circulation 101(17):2053–2059PubMedCrossRef

11.

Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107(9):1278–1283CrossRef

12.

Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ, MOXCON Investigators (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5(5):659–667PubMedCrossRef

13.

Packer M, Bristow MR, Cohn JN (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334(1349):1355

14.

CIBIS-II Investigators and Committees (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet 353(9):13

15.

Sobotka PA, Krum H, Böhm M, Francis DP, Schlaich MP (2012) The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep 14(3):285–292PubMedCrossRef

16.

Sadoshima J, Xu Y, Slayter HS (1993) Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vivo. Cell 75:977–984PubMedCrossRef

17.

Sadoshima J, Izumo S (1993) Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73:413–423PubMedCrossRef

18.

Weber KT, Brilla CG (1991) Pathological hypertrophy and the cardiac interstitium. Fibrosis and the renin–angiotensin–aldosterone system. Circulation 83:1849–1865PubMedCrossRef

19.

Brilla CG, Zhou G, Matsubara L, Weber KT (1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Immunol 26:809–820

20.

Dostal DE, Baker KM (1999) The cardiac renin–angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 85:643PubMedCrossRef

21.

Marcus LS, Hart D, Packer M (1996) Hemodynamics and renal excretory effects of human brain natriuretic peptide infusion In patients with congestive heart failure. Circulation 94:3184–3189PubMedCrossRef

22.

Hobbs RE, Miller LW, Bott-Silverman C (1996) Hemodynamics effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 78:896–901PubMedCrossRef

23.

Yamamoto K, Burnett JCJ, Redfield MM (1997) Effects of the endogenous natriuretic peptide system on ventricular and coronary function in the failing heart. Am J Physiol 273:H2406–H2414PubMed

24.

Clarkson PBM, Wheeldon NM, Macleod C (1995) Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects. Clin Sci 88:159–164PubMedCrossRef

25.

Krum H, Schlaich M, Sobotka P, Scheffers I, Kroon AA, de Leeuw PW (2011) Novel procedure- and device-based strategies in the management of systemic hypertension. Eur Heart J 32(5):537–544PubMedCrossRef

26.

Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del Bo A, Sala C, Bolla GB, Pozzi M (1995) Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 92(11):3206–3211PubMedCrossRef

27.

Leier CV, Dei Cas L, Metra M (1994) Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 128(3):564–574PubMedCrossRef

28.

Lee WH, Packer M (1986) Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73(2):257–267PubMedCrossRef

29.

Thomas G, Shishehbor MH, Bravo EL, Nally JV (2012) Renal denervation to treat resistant hypertension: guarded optimism. Cleve Clin J Med 79(7):501–510PubMedCrossRef

30.

Smithwick RH (1955) Hypertensive vascular disease: results of and indications for splanchnicectomy. J Chronic Dis 1(5):477–496PubMedCrossRef

31.

Webster W Jr, Scherlag BJ, Scherlag MA, Schauerte P (1999) Method and apparatus for transvascular treatment of tachycardia and fibrillation. US Patent 6,292,695. June 17, 1999

32.

Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671):1275–1281PubMedCrossRef

33.

Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT et al (2013) Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 34(28):2132–2140PubMedPubMedCentralCrossRef

34.

Ahmed H, Neuzil P, Skoda J, Petru J, Sediva L, Schejbalova M et al (2012) Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv 5:758–765PubMedCrossRef

35.

Ormiston JA, Watson T, van Pelt N, Stewart R, Haworth P, Stewart JT et al (2013) First-in-human use of the OneShot renal denervation system from Covidien. EuroIntervention 8:1090–1094PubMedCrossRef

36.

Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M (2012) First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention 8:57–61PubMedCrossRef

37.

Stefanadis C, Toutouzas K, Vlachopoulos C, Tsioufis C, Synetos A, Pietri P et al (2013) Chemical denervation of the renal artery with vincristine for the treatment of resistant arterial hypertension: first-in-man application. Hell J Cardiol 54:318–321

38.

Okada T, Pellerin O, Savard S, Curis E, Monge M, Frank M, Bobrie G, Yamaguchi M, Sugimoto K, Plouin PF, Azizi M, Sapoval M (2015) Eligibility for renal denervation: anatomical classification and results in essential resistant hypertension. Cardiovasc Interv Radiol 38(1):79–87. doi:10.1007/s00270-014-0865-6 CrossRef

39.

Id D, Kaltenbach B, Bertog SC, Hornung M, Hofmann I, Vaskelyte L, Sievert H (2013) Does the presence of accessory renal arteries affect the efficacy of renal denervation? JACC Cardiovasc Interv 6(10):1085–1091PubMedCrossRef

40.

Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B, Blicher MK, Severino F, Wuerzner G, Taylor A, Pechère-Bertschi A, Jokhaji F, Fadl Elmula FE, Rosa J, Czarnecka D, Ehret G, Kahan T, Renkin J, Widimsky JI Jr, Jacobs L, Spiering W, Burnier M, Mark PB, Menne J, Olsen MH, Blankestijn PJ, Kjeldsen S, Bots ML, Staessen JA (2014) Eligibility for renal denervation: experience at 11 European expert centers. Hypertension 63(6):1319–1325PubMedCrossRef

41.

Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD (2014) Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383(9917):622–629PubMedCrossRef

42.

Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP (2014) Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 35(26):1752–1759PubMedCrossRef

43.

Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370(15):1393–1401PubMedCrossRef

44.

Templin C, Jaguszewski M, Ghadri JR, Sudano I, Gaehwiler R, Hellermann JP, Schoenenberger-Berzins R, Landmesser U, Erne P, Noll G, Lüscher TF (2013) Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity catheter system and the EnligHTN multi-electrode renal denervation catheter. Eur Heart J 34(28):2141–2148. doi:10.1093/eurheartj/eht141 PubMedPubMedCentralCrossRef

45.

Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC (2012) Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 59(10):901–909PubMedCrossRef

46.

Mahfoud F, Urban D, Teller D, Linz D, Stawowy P, Hassel JH, Fries P, Dreysse S, Wellnhofer E, Schneider G, Buecker A, Schneeweis C, Doltra A, Schlaich MP, Esler MD, Fleck E, Böhm M, Kelle S (2014) Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J 35(33):2224–2231PubMedCrossRef

47.

Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D’Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O’Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators (2015) 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: The SYMPLICITY HTN-3 trial. J Am Coll Cardiol 65(13):1314–1321. doi:10.1016/j.jacc.2015.01.037 PubMedCrossRef

48.

Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O’Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL (2015) Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 36(4):219–227PubMedCrossRef

49.

Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G, Renal Denervation for Hypertension (DENERHTN) Investigators (2015) Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. doi:10.1016/S0140-6736(14)61942-5

50.

Xie Y, LiuLiu Q, Xu Y, Gao J, Yan P, Zhang W, Sun J, Wang M, Jin H, Jiang J, Liu Z (2014) Effect of catheter-based renal sympathetic denervation in pigs with rapid pacing induced heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 42(1):48–52PubMed

51.

Tan LH, Li XG, Guo YZ, Tang XH, Yang K, Jiang WH (2013) Effect of renal sympathetic denervation on left ventricular hypertrophy and inflammatory factors in spontaneously hypertensive rats. Zhejiang Da Xue Xue Bao Yi Xue Ban 42(5):550–555PubMed

52.

Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, Hamady M, Hughes AD, Sever PS, Sobotka PA, Francis DP (2013) First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 162(3):189–192PubMedCrossRef

53.

Schirmer SH, Sayed MM, Reil JC, Ukena C, Linz D, Kindermann M, Laufs U, Mahfoud F, Böhm M (2014) Improvements of left-ventricular hypertrophy and diastolic function following renal denervation—effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol 63(18):1916–1923PubMedCrossRef

54.

Verloop WL, Beeftink MM, Nap A, Bots ML, Velthuis BK, Appelman YE, Cramer MJ, Agema WR, Scholtens AM, Doevendans PA, Allaart CP, Voskuil M (2013) Renal denervation in heart failure with normal left ventricular ejection fraction. Rationale and design of the DIASTOLE (DenervatIon of the renAl Sympathetic nerves in hearT failure with nOrmal Lv Ejection fraction) trial. Eur J Heart Fail 15(12):1429–1437PubMedCrossRef

Titel: A perspective on sympathetic renal denervation in chronic congestive heart failure
verfasst von: Raef Madanieh
Mohammed El-Hunjul
Hassan Alkhawam
Constantine E. Kosmas
Abed Madanieh
Timothy J. Vittorio
Publikationsdatum: 01.01.2016
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 1/2016
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-015-9516-5

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

MELAS syndrome and cardiomyopathy: linking mitochondrial function to heart failure pathogenesis

Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure

Left atrial strain: a new parameter for assessment of left ventricular filling pressure

Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes